Thaum Lub Peb Hlis 12, 2026, Clinicaltrial lub vev xaib tau pom tias Smeglutide qhov ntswg tsuag ntawm Shiling Pharmaceutical tau sau npe rau theem|kev tshawb fawb soj ntsuam hauv cov neeg rog rog rog lossis rog rog, uas yog thawj qhov kev sim tshuaj ntawm cov tshuaj.
Semaglutide hmoov CAS 910463-68-2
1.Peb muab
(1) Tablet
(2) Cov
(3) Capsule
(4) Txau
(5) API (Ntshiab hmoov)
(6) Pill press machine
https://www.achievechem.com/pill-xwm
2.Customization:
Peb yuav sib tham tus kheej, OEM / ODM, Tsis muaj hom, rau kev tshawb nrhiav kev ruaj ntseg nkaus xwb.
PIB: BM-2-4-008
Semaglutide CAS 910463-68-2
Kev tshuaj xyuas: HPLC, LC-MS, HNMR
Kev them nyiaj yug Technology: R&D Dept.-4
Peb muabSemaglutide hmoov, thov xa mus rau lub vev xaib hauv qab no kom paub meej cov lus qhia tshwj xeeb thiab cov ntaub ntawv khoom.
Khoom siv:https://www.bloomtechz.com/synthetic-chemical/peptide/semaglutide-powder-cas-910463-68-2.html
Txoj kev tshawb no tau npaj los ua hauv Tebchaws Meskas, thiab 60 tus neeg yuav suav nrog. Lub hom phiaj yog txhawm rau kuaj kev nyab xeeb, kev ua siab ntev thiab cov tshuaj pharmacokinetics ntawm Smeagzentide qhov ntswg tshuaj tsuag hauv cov neeg laus rog rog lossis rog rog piv nrog cov placebo thiab kev tswj kom zoo.
Thawj qhov kev tshawb fawb ntawm semaglutide tau ua los ntawm Novo Nordisk. Raws li ib tug pioneering tshuaj nyob rau hauv lub GLP-1 teb, semaglutide tau nrov thoob ntiaj teb txij li thaum nws tso tawm, nrog ib tug staggering $34.608 billion nyob rau hauv 2025. Txawm hais tias nws tseem tsis tau nce mus rau lub zwm txwv ntawm tus huab tais yeeb tshuaj, nws tseem yog ib tug tiag tiag "nyiaj tshuab luam ntawv".
Smeglutide ntawm Shiling Pharmaceutical yog ib qho tshuaj tsuag qhov ntswg tsim raws li mucosal xa khoom platform. Nws qhov zoo yog nyob rau hauv: zam qhov kev cuam tshuam thawj zaug thiab txhim kho bioavailability; Kev tswj hwm tshuaj tsis muaj kev cuam tshuam, kev ua raws cai siab, muaj txiaj ntsig zoo rau kev kho kab mob thiab kev tswj hwm; Kev siv tshuaj yooj yim thiab kev tswj hwm tus kheej, nws xav tias yuav dhau los ua daim ntawv thib peb ntawm kev noj tshuaj tom qab txhaj tshuaj thiab npaj qhov ncauj.
Hengrui insulin / GLP-1 compound npaj Shudi insulin Norilside thov rau kev lag luam tawm
Thaum Lub Peb Hlis 13, 2026, Hengrui Pharmaceutical tau txais Daim Ntawv Pom Zoo Tshaj Tawm los ntawm Lub Xeev Food and Drug Administration, thiab daim ntawv thov kev lag luam ntawm lub tuam txhab Class 1 cov tshuaj tshiab, ntev - ua cov tshuaj insulin analog / glucagon zoo li peptide-1 (GLP-1) receptor agonist tsau tshuaj npaj, Sudirinide thiab No. Cov lus qhia tau hais tseg yog: muaj feem xyuam rau cov neeg laus mob ntshav qab zib hom 2 uas tswj cov phev ntshav tsis zoo, thiab ua ke nrog lwm cov tshuaj hypoglycemic ntawm qhov ncauj los ntawm kev noj zaub mov thiab kev tawm dag zog los txhim kho cov ntshav qab zib.
Daim ntawv thov kev sau npe no yog ua raws li ob theem tseem ceeb ntawm kev tshawb fawb soj ntsuam (cov lej kawm: HR17031-301, HR17031-302) ntawm insulin suldi thiab noriglycopeptide txhaj (R&D code: HR17031) hauv cov neeg laus uas muaj ntshav qab zib hom 2 (12DM), uas muaj ntau qhov chaw, randomized, kev siv tshuaj zoo, qhib thiab kaw. Ob txoj kev tshawb fawb tau ua los ntsuas qhov ua tau zoo thiab kev nyab xeeb ntawm Shudi insulin thiab Norilside txhaj tshuaj thiab tswj cov tshuaj hauv T2DM cov neeg mob uas tsis muaj ntshav qabzib tswj tau kho nrog cov tshuaj tiv thaiv qhov ncauj hypoglycemic thiab basal insulin therapy, raws li.
HR17031-301 txoj kev tshawb fawb tau coj los ntawm xibfwb Ji Linong los ntawm Peking University People's Hospital, nrog rau tag nrho 54 lub chaw pib thoob tebchaws thiab 401 tus neeg tuaj koom randomly cuv npe. Txoj kev tshawb fawb HR17031-302 tau coj los ntawm xibfwb Chen Liming los ntawm Tianjin Medical University Zhu Xianyi Memorial Tsev Kho Mob, nrog rau tag nrho 65 lub chaw pib thoob tebchaws thiab 393 tus neeg tuaj koom. Cov txiaj ntsig ntawm ob txoj kev tshawb fawb pom tau tias qhov kawg ntawm suldi insulin thiab noriglycopeptide txhaj tshuaj yog qhov zoo dua li ntawm pawg tswj xyuas, thiab kev nyab xeeb nruab nrab thiab ntev thiab kev ua siab ntev ntawm suldi insulin thiab noriglycopeptide txhaj rau cov neeg mob ntshav qab zib hom 2 yog qhov zoo.
Qilu Pharmaceutical's "Oral Simeglutide" Launch Phase Clinical Trial
Thaum Lub Peb Hlis 16, 2026, lub chaw soj ntsuam kuaj tshuaj thiab cov ntaub ntawv nthuav tawm platform tau pom tias Qilu Pharmaceutical tau pib thawj theem kev soj ntsuam ntawm qhov ncauj semaglutide biosimilar QLG1091. Txoj kev tshawb no yog ntau qhov chaw, randomized, ob - qhov muag tsis pom, zoo tshuaj tswj kev kuaj mob (n=478), uas yog lub hom phiaj los ntsuas qhov ua tau zoo thiab kev nyab xeeb ntawm GLG1091 piv nrog qhov ncauj smectil peptide (Lus Askiv lub npe: Rybelsus, Suav lub npe lag luam:
Novexin @) hauv cov neeg mob uas muaj ntshav qab zib hom 2 uas tswj cov ntshav qabzib tsis zoo tom qab kev kho mob ntawm cov leeg hauv nruab nrab thiab ob leeg. Lub ntsiab lus kawg ntawm txoj kev tshawb no yog kev hloov pauv hauv glycated hemoglobin (HbA1c) qib los ntawm qhov pib ntawm lub lim tiam 26.
Thawj lub tuam txhab tshawb fawb, Sinovac Biotech, yog GLP-1 receptor (GLP-1 R) agonist tsim los ntawm Novo Nordisk. Nws daim ntawv txhaj tshuaj Ozempic (Suav lub npe lag luam: Novotec) thiab Wegowy8 (Suav lub npe lag luam: Novowy8 @) tau pom zoo rau kev ua lag luam hauv Tebchaws Meskas thaum Lub Kaum Ob Hlis 2017 thiab Lub Rau Hli 2021, feem. Daim ntawv hais lus Rybelsus @ tau pom zoo rau kev ua lag luam hauv Tebchaws Meskas thaum lub Cuaj Hli 2019. Raws li Novo Nordisk daim ntawv qhia txog nyiaj txiag, hauv 2025, peb hom ntawm Simegapeptide yuav ua rau tag nrho cov nyiaj tau los ntawm 34.6 billion US dollars.